#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Osteopetrosis Andersen-Tawil syndrome Cytomegalovirus infection Neuroendocrine carcinoma metastatic Hepato-lenticular degeneration Phaeochromocytoma Hydrocephalus ABO haemolytic disease of newborn Chronic myeloid leukaemia (in remission) Vulval cancer recurrent Hereditary motor and sensory neuropathy Osteogenesis imperfecta Cholangiocarcinoma Vascular malformation Insulinoma More trials…

    Learn about Rare Diseases

    Cystic fibrosis – Life with Disease Proteus syndrome – Basic Information Ornithine transcarbamoylase deficiency – Treatment Haemolytic uraemic syndrome Myxofibrosarcoma – Basic Information Waldenstrom’s macroglobulinaemia Congenital nephrogenic diabetes insipidus – Life with Disease Chondrosarcoma – Diagnostics Rhabdoid tumour – Trials in Disease Familial amyotrophic lateral sclerosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Revumenib DCC-3084 Alectinib Hydrochloride ZINC CHLORIDE Ribociclib Festuca Elatior Pollen Extract Ralinepag Oxybuprocaine Hydrochloride Bemnifosbuvir Hemisulfate Cpk850 VHB937 Iberdomide 534 Immunostimulants Ifosfamide Allogeneic Faecal Microbiota IHMA-2121771-2 Axitinib Pirfenidone KETOROLAC TROMETAMOL More therapies…

    Learn about Your Condition

    Testis cancer Brain injury Oxygen therapy Immune thrombocytopenia Deep vein thrombosis Pleural mesothelioma Abdominal pain Hyperchylomicronaemia Plasma cell myeloma refractory Status epilepticus Coronary artery dissection Immune-mediated myositis Juvenile psoriatic arthritis Pre-eclampsia Affective disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

T-cell type acute leukaemia

  • Study of CART84 Treatment for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia refractory
    • T-cell type acute leukaemia
    • Acute myeloid leukaemia
    Spain

  • Long-term Follow-up Study for Patients with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Treated with OC-1 Cells

    Recruiting

    3 1 1
    Investigated Drugs:
    • Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A
    Spain

  • Study on the Safety and Effectiveness of OC-1 Therapy for Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma

    Recruiting

    1 1 1
    Investigated Diseases:
    • T-cell type acute leukaemia
    • Precursor T-lymphoblastic lymphoma/leukaemia recurrent
    Investigated Drugs:
    • Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A
    Spain

  • Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Bortezomib
    • Daunorubicin
    • Isatuximab
    Germany

  • Study of CD7-CART01, Cyclophosphamide, and Fludarabine Phosphate for Children and Young Adults with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Cd7-Cart01
    • Fludarabine Phosphate
    • Cyclophosphamide
    Italy

  • Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • T-cell type acute leukaemia
    Investigated Drugs:
    • Tofacitinib
    • Azacitidine
    • Everolimus
    Czechia France Germany The Netherlands Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!